Ibio Inc (A:IBIO)

Mar 27, 2024 09:31 am ET
Thinking about buying stock in Ibio, Village Farms International, MariaDB, Nexgel, or Urban Outfitters ?
NEW YORK, March 27, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, VFF, MRDB, NXGL, and URBN.
Mar 27, 2024 07:00 am ET
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic...
Mar 26, 2024 07:35 pm ET
iBio Announces $15.0 Million Private Placement
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing...
Feb 26, 2024 07:45 am ET
iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”),...
Jan 25, 2024 08:31 am ET
Thinking about buying stock in Ibio Inc, Nokia, C4 Therapeutics, 1847 Holdings, or CleanSpark?
NEW YORK, Jan. 25, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, NOK, CCCC, EFSH, and CLSK.
Jan 16, 2024 08:15 am ET
iBio Announces Participation in 23rd Annual PepTalk Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matthew P. Greving Ph.D., its Vice President and Head of Platform Technologies and Machine Learning, will give a...
Dec 26, 2023 07:15 am ET
iBio Amends and Extends Maturity of Credit Agreement
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into...
Dec 05, 2023 08:31 am ET
Thinking about buying stock in Mongodb, Aquestive Therapeutics, Sovos Brands, Travere Therapeutics, or Ibio Inc?
NEW YORK, Dec. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MDB, AQST, SOVO, TVTX, and IBIO.
Dec 05, 2023 08:00 am ET
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and...
Nov 27, 2023 05:20 pm ET
iBio Announces Reverse Stock Split
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November...
Nov 01, 2023 08:24 am ET
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody...
Oct 10, 2023 08:00 am ET
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matt Greving Ph.D., its Vice President of Platform Technologies and Machine Learning, has been selected to present...
Oct 02, 2023 06:45 am ET
iBio Explains Recent Filing of Registration Statement
In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 (the “Post-Effective Amendment”) filed on Friday, September 29, 2023 with the United States Securities and Exchange Commission (“SEC”), iBio...
Sep 27, 2023 04:19 pm ET
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the...
Sep 21, 2023 04:05 pm ET
iBio Announces Amendment to Credit Agreement with Woodforest
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and Woodforest National Bank (“Woodforest”) have entered into a sixth...
Aug 14, 2023 04:15 pm ET
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced positive pre-clinical in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x...
Jun 27, 2023 08:00 am ET
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer,...
Jun 12, 2023 04:15 pm ET
iBio Forges Research Collaboration with the National Institutes of Health
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the Company has entered into a research collaboration with the National Institute of Allergy and Infectious...
Jun 06, 2023 08:00 am ET
iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for...
May 09, 2023 04:30 pm ET
iBio to Participate in the JMP Securities Life Sciences Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in...
Apr 04, 2023 04:05 pm ET
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by its VP & Head of Machine Learning & Platform Technologies, Matt Greving, Ph.D., during...
Mar 31, 2023 08:10 am ET
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of...
Feb 17, 2023 07:36 am ET
Thinking about buying stock in iBio, Jasper Therapeutics, BioSig Technologies, DraftKings, or Eos Energy?
NEW YORK, Feb. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, JSPR, BSGM, DKNG, and EOSE.
Feb 16, 2023 04:47 pm ET
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the disclosure of MUC16 as the target of it’s latest immune-oncology program. MUC16 is a well-known cancer target...
Jan 05, 2023 08:00 am ET
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning...
Dec 09, 2022 04:05 pm ET
iBio Announces Closing of $3.5 Million Underwritten Public Offering
iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common...
Dec 06, 2022 11:27 pm ET
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common...
Dec 06, 2022 04:01 pm ET
iBio Announces Proposed Underwritten Public Offering
iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock...
Dec 06, 2022 08:00 am ET
iBio to Participate in the JMP Securities Hematology and Oncology Summit
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a virtual fireside chat at the JMP...
Dec 05, 2022 08:00 am ET
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California,...
Dec 02, 2022 04:30 pm ET
iBio Announces CEO Departure
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the “Board”) and Thomas F. Isett, the Company’s Chief Executive Officer, have agreed that Mr....
Nov 03, 2022 08:00 am ET
iBio Accelerates Transformation to AI-Powered Biotech
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) an AI-driven innovator of precision antibody immunotherapies, announces it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its...
Sep 27, 2022 04:10 pm ET
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year...
Sep 21, 2022 08:30 am ET
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the...
Aug 16, 2022 09:00 am ET
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today provided an update on IBIO-202, its next-generation vaccine candidate...
May 18, 2022 08:00 am ET
iBio to Participate in the H.C. Wainwright Global Investment Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will participate virtually in the H.C....
May 12, 2022 04:05 pm ET
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces its financial results for the fiscal quarter ended March 31,...
May 09, 2022 08:00 am ET
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, announced today a poster presentation on IBIO-101, the Company's monoclonal...
May 05, 2022 04:30 pm ET
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 third quarter...
May 02, 2022 08:00 am ET
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today that it will present a poster at the 18th Annual Protein &...
Mar 11, 2022 08:00 am ET
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its Chairman & CEO, Tom Isett, will present...
Feb 14, 2022 04:05 pm ET
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31,...
Feb 07, 2022 04:30 pm ET
iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter...
Jan 26, 2022 09:00 am ET
iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today shared an update on its lead COVID-19 vaccine program, IBIO-202. iBio...
Jan 04, 2022 04:30 pm ET
iBio Announces Participation in the H.C. Wainwright BioConnect Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it will participate in the H.C. Wainwright...
Dec 22, 2021 09:25 am ET
iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it has adjourned its 2021 Annual Meeting of...
Dec 21, 2021 09:20 am ET
iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, provides the following link to listen virtually to the 2021 Annual...
Dec 10, 2021 08:30 am ET
iBio Announces Partial Adjournment of Annual Meeting to December 22
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its annual meeting of stockholders (the...
Nov 30, 2021 08:00 am ET
ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that Institutional Shareholder Services, Inc....
Nov 29, 2021 08:45 am ET
Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced an update for its lead COVID-19 vaccine program, IBIO-202, in...
Nov 17, 2021 04:30 pm ET
Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that Glass Lewis and Co., LLC (“Glass Lewis”), a...
Nov 15, 2021 04:05 pm ET
iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended September 30,...
Nov 15, 2021 01:00 pm ET
iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced a research collaboration with the University of Texas...
Nov 08, 2021 04:30 pm ET
iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 first quarter...
Nov 03, 2021 04:47 pm ET
iBio Acquires FastPharming Manufacturing Facility®
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based  FastPharming System, today announced it has purchased the manufacturing facility it previously...
Oct 26, 2021 08:35 am ET
iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today urged its stockholders to vote “FOR” all proposals put forth...
Sep 27, 2021 07:30 am ET
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced its financial results for the fiscal fourth quarter...
Sep 20, 2021 04:30 pm ET
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the Company’s Chairman & CEO, Tom Isett, and...
Sep 20, 2021 07:30 am ET
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal fourth quarter and...
Sep 07, 2021 04:30 pm ET
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it will participate in the H.C. Wainwright...
Aug 26, 2021 07:00 am ET
iBio Appoints William D. Clark to its Board of Directors
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, announced today the appointment of William D. (Chip) Clark to its Board of...
Aug 25, 2021 07:30 am ET
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced that it has signed a definitive worldwide exclusive license...
Jul 16, 2021 08:30 am ET
Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?
NEW YORK, July 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.
Jul 15, 2021 05:10 pm ET
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (“N...
Jul 08, 2021 04:15 pm ET
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein...
Jun 11, 2021 09:31 am ET
Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?
NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, GRAY, JAGX, IBIO, and APTX.
Jun 09, 2021 04:30 pm ET
iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today the appointment of Evert (Eef) Schimmelpennink to its Board of Directors, effective immediately. In an...
May 19, 2021 04:30 pm ET
iBio to Present at the UBS Global Healthcare Virtual Conference
iBio, Inc. (NYSE:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that management will present an update on the Company’s business at the UBS Global Healthcare Virtual...
May 17, 2021 07:00 am ET
iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended March 31, 2021. “Our focus on strategy execution was...
May 10, 2021 08:15 am ET
iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 third quarter financial results before market open on Monday, May 17,...
May 06, 2021 04:15 pm ET
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit...
May 04, 2021 05:00 pm ET
iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. (“Fraunhofer USA”). The parties’...
Mar 09, 2021 04:30 pm ET
iBio to Participate in the 33rd Annual Roth Conference
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually from March 15-17,...
Feb 16, 2021 04:05 pm ET
iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended December 31, 2020. “We successfully executed against our...
Feb 16, 2021 08:00 am ET
iBio Appoints Robert M. Lutz as Chief Financial & Business Officer
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Robert M. Lutz as its Chief Financial & Business Officer (“CFBO”), effective March 4, 2021....
Feb 09, 2021 04:30 pm ET
iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 second quarter financial results after market close on Tuesday, February...
Feb 08, 2021 09:45 am ET
Thinking about buying stock in InspireMD, iBio, Nokia, Novan, or T2 Biosystems?
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NSPR, IBIO, NOK, NOVN, and TTOO.
Feb 04, 2021 08:31 am ET
Thinking about buying stock in Apple, Digital Turbine, Draftkings, Canada Goose Holdings, or iBio?
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, APPS, DKNG, GOOS, and IBIO.
Jan 22, 2021 07:30 am ET
Thinking about buying stock in iBio, Fluidigm Corp, Atossa Therapeutics, BioCryst Pharmaceuticals, or GameStop?
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, FLDM, ATOS, BCRX, and GME.
Jan 13, 2021 07:30 am ET
Thinking about buying stock in iBio, Plug Power, Canoo, Gevo, or Biolase?
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, PLUG, GOEV, GEVO, and BIOL.
Dec 28, 2020 07:30 am ET
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January...
Dec 11, 2020 08:31 am ET
Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?
NEW YORK, Dec. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO.
Dec 10, 2020 04:30 pm ET
iBio Announces Closing of its Public Offering of Common Stock
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten public offering of approximately 29.7 million shares of its common stock for...
Dec 08, 2020 09:45 am ET
Thinking about buying stock in Sundial Growers, iBio, Cinedigm Corp, AMC Entertainment, or HollySys Automation?
NEW YORK, Dec. 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, IBIO, CIDM, AMC, and HOLI.
Dec 08, 2020 08:55 am ET
iBio Announces Pricing of $35 Million Public Offering of Common Stock
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing of its underwritten public offering of approximately 29.7 million shares of its common stock for...
Dec 07, 2020 04:01 pm ET
iBio Announces Proposed Public Offering of Common Stock
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an underwritten public offering of its common stock. In addition, iBio has granted the underwriter a 30-day...
Dec 02, 2020 07:30 am ET
Thinking about buying stock in Aurora Cannabis, Pfizer, Viveve Medical, NetApp, or iBio?
NEW YORK, Dec. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, PFE, VIVE, NTAP, and IBIO.
Dec 01, 2020 04:30 pm ET
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first Statement of Work (“SoW”) under a Master Services...
Nov 24, 2020 07:30 am ET
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled “Materials...
Nov 16, 2020 04:05 pm ET
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal quarter ended September 30, 2020. “We made tremendous strides during...
Nov 12, 2020 08:00 am ET
iBio to Participate in Alliance Global Partners’ Virtual Healthcare Symposium
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that management will participate in Alliance Global Partners’ Virtual Healthcare Symposium on November 19,...
Nov 05, 2020 04:30 pm ET
iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 first quarter financial results after market close on Monday, November 16,...
Nov 03, 2020 07:30 am ET
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer (“COO”), effective December 1, 2020. Mr....
Oct 15, 2020 04:05 pm ET
Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Gary Sender to its Board of Directors, effective as of October 14, 2020. Mr. Sender will...
Oct 15, 2020 07:30 am ET
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr....
Oct 14, 2020 04:05 pm ET
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Dr. Linda Armstrong to its Board of Directors, effective immediately. Dr. Armstrong has...
Oct 13, 2020 04:05 pm ET
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal year ended June 30, 2020, which included record revenues of over $1.1...
Oct 05, 2020 07:30 am ET
iBio Regains Compliance with NYSE American Continued Listing Standards
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that on October 1, 2020, the Company received written notice from the NYSE American LLC (“NYSEA” or...
Oct 02, 2020 07:00 am ET
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has entered into a Master Services Agreement (“MSA”) with Boston-based Safi Biosolutions, Inc....
Sep 09, 2020 08:45 am ET
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has selected IBIO-201, its LicKM™-ubunit vaccine, as its leading candidate for the prevention...
Aug 28, 2020 07:15 am ET
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced that it has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc....
Aug 10, 2020 07:15 am ET
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided an update on one of its proprietary vaccine candidates being designed to prevent infection from...
Aug 05, 2020 09:31 am ET
Thinking about buying stock in iBio Inc, Whiting Petroleum, IMV Inc, Microvision Inc, or Jumia Technologies?
NEW YORK, Aug. 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, WLL, IMV, MVIS, and JMIA.
Aug 03, 2020 09:31 am ET
Thinking about trading options or stock in Nio Inc, iBio Inc, Dynavax Technologies, Apple Inc, or Walt Disney?
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, IBIO, DVAX, AAPL, and DIS.
Jul 30, 2020 10:35 am ET
Thinking about buying stock in Edesa Biotech, iBio Inc, Pfizer Inc, Lexicon Pharmaceuticals, or Apache Corp?
NEW YORK, July 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EDSA, IBIO, PFE, LXRX, and APA.
Jul 28, 2020 10:45 am ET
Thinking about buying stock in Moderna, Ocugen Inc, Advanced Micro Devices, iBio Inc, or Taiwan Semiconductor?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, OCGN, AMD, IBIO, and TSM.
Jul 22, 2020 10:35 am ET
Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc?
NEW YORK, July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, IBIO, ACHV, NTEC, and AAPL.
Jul 20, 2020 09:31 am ET
Thinking about buying stock in iBio Inc, Idera Pharmaceuticals, PDS Biotechnology, Checkpoint Therapeutics, or Norwegian Cruise Line Holdings?
NEW YORK, July 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, IDRA, PDSB, CKPT, and NCLH.
Jul 15, 2020 09:31 am ET
Thinking about buying stock in Can Fite Biopharma, RTI Surgical Holdings, JetBlue Airways, iBio Inc, or Sunrun Inc?
NEW YORK, July 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, RTIX, JBLU, IBIO, and RUN.
Jul 08, 2020 09:31 am ET
Thinking about buying stock in VBI Vaccines, Electrameccanica Vehicles, Ibio Inc, American Airlines, or Workhorse Group?
NEW YORK, July 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VBIV, SOLO, IBIO, AAL, and WKHS.
Jun 26, 2020 06:45 am ET
iBio to be Added to the Russell 2000® and Russell 3000® Indexes
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics innovator and contract manufacturing organization, today announced that it will be added to the Russell 2000® and Russell 3000® indexes as part of this year's reconstitution....
Jun 24, 2020 06:45 am ET
iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that IBM Watson Health has selected iBio to receive 18 months of use of the IBM Clinical...
Jun 04, 2020 09:31 am ET
Thinking about buying stock in Cinedigm Corp, iBio Inc, Nio Inc, American Airlines, or Chesapeake Energy Corp?
NEW YORK, June 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CIDM, IBIO, NIO, AAL, and CHK.
Jun 04, 2020 07:00 am ET
iBio Announces Second COVID-19 Vaccine Program
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced initiation of preclinical immunization studies for its second COVID-19 vaccine platform. The...
Apr 27, 2020 04:15 pm ET
iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today provided an update on its COVID-19 vaccine manufacturing capacity and announced that it has joined the...
Apr 09, 2020 07:30 am ET
iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology innovator, today announced the signing of two Master Services Agreements (the MSAs”) and a Memorandum of Understanding (the...
Apr 01, 2020 09:31 am ET
Thinking about buying stock in Chembio Diagnostics, General Electric, iBio Inc, Peloton, or AT&T?
NEW YORK, April 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEMI, GE, IBIO, PTON, and T.
Mar 26, 2020 04:20 pm ET
iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into a second Statement of Work under its Master Joint Development Agreement (the “MJDA”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”).  Signed in...
Mar 26, 2020 07:30 am ET
iBio Announces Advancement of COVID-19 Vaccine Program
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that immunization studies for its SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are...
Mar 20, 2020 07:30 am ET
iBio Joins the Alliance for Biosecurity
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that it has joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies –...
Mar 18, 2020 08:00 am ET
iBio Announces Development of Proprietary COVID-19 Vaccine Candidates
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced its progress towards developing vaccine candidates for preventing infection from the SARS-CoV-2...
Mar 12, 2020 04:45 pm ET
iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the appointment of accomplished life sciences executive, Thomas F. Isett, as its Co-Chairman and Chief Executive Officer. Mr. Isett, a current member of iBio’s Board of...
Mar 02, 2020 04:30 pm ET
iBio, Inc. Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split
IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that its Board of Directors has decided it will not seek authority from the shareholders at the 2019 Annual Meeting (“Annual Meeting”) to effect a reverse split of its...
Feb 06, 2020 04:30 pm ET
iBio, Inc. Announces Postponement of Annual Meeting
IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that the 2019 annual meeting of stockholders (the “Annual Meeting”) originally scheduled to be held on Monday, February 10, 2020, has been postponed and will now be held on...
Feb 03, 2020 04:15 pm ET
iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine
In response to investor and media inquiries regarding their initiatives to address the coronavirus outbreak, iBio, Inc. (NYSE AMERICAN:IBIO) and Beijing CC-Pharming Ltd., today announced their collaboration to develop and test a new 2019-nCoV...
Jan 16, 2020 08:00 am ET
iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance
IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that it has received notice from NYSE American LLC (the “Exchange”) that NYSE Regulation has accepted the Company’s November 15, 2019 plan to regain compliance with the...
Jan 06, 2020 09:15 am ET
iBio Initiates New Litigation Against Fraunhofer
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio”), a biologics innovator and contract manufacturer, announced today that it filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft...
Dec 23, 2019 09:30 am ET
EdgePoint announces collaboration with iBio CDMO to implement AI/Blockchain driven TrustPoint Vision Technology in its Texas cGMP facility
EdgePoint AI, a wholly-owned division of Mateon Therapeutics, Inc (OTC:MATN) announced today that it has entered into a collaboration with iBio, Inc. (NYSE AMERICAN:IBIO) to deploy the technology solutions TrustPoint Vision Fabric and TrustPoint...
Dec 23, 2019 08:30 am ET
iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence (“AI”)/blockchain-driven...
Dec 16, 2019 04:15 pm ET
iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming
iBio, Inc. (NYSE AMERICAN:IBIO) presented results of the application of its new FastGlycaneering Development Service™ to enhance potency of recombinant proteins at last week’s Antibody Engineering & Therapeutics conference in San Diego, CA....
Dec 13, 2019 05:00 pm ET
iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
iBio, Inc. (NYSE American: IBIO) (“iBio” or the “Company”), a leader in plant-based biologics manufacturing, announced today that on December 9, 2019, the Company received a letter from NYSE American LLC (“NYSE American” or the “Exchange”)...
Dec 10, 2019 04:44 pm ET
iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production
iBio, Inc. (NYSE AMERICAN:IBIO) today unveiled the FastGlycaneering Development Service™, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators and biosimilar...
Dec 03, 2019 12:31 pm ET
iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it is now part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (“ARMI”). Headquartered in Manchester, New Hampshire, ARMI is the 12th...
Dec 02, 2019 04:15 pm ET
iBio to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
iBio, Inc. (NYSE AMERICAN:IBIO) announced today that management will present an update on the Company’s business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 11:30 a.m. Eastern Time. The live and...
Oct 25, 2019 08:30 am ET
iBio, Inc. Prices $5,000,000 Public Offering
IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $5,000,000, before deducting underwriting discounts, commissions and...
Oct 22, 2019 04:30 pm ET
iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”) announced today that on October 16, 2019, the Company received notice from NYSE American (the “Exchange”) that the Company currently is below the Exchange’s continued listing standards set...
Sep 17, 2019 04:15 pm ET
iBio’s Collaboration with South Africa’s AzarGen Biotechnologies Advances to Next Stage
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into the initial Statement of Work (“SOW1”) under its Memorandum of Understanding (“MOU”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”). Following...
Aug 27, 2019 09:31 am ET
Thinking about buying stock in Canopy Growth, Ibio, Momo, Micron Technology, or Ossen Innovation?
NEW YORK, Aug. 27, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, IBIO, MOMO, MU, and OSN.
Aug 26, 2019 05:30 pm ET
iBio and CC-Pharming Expand Business Collaboration in China
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd. by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product...
Aug 20, 2019 09:31 am ET
Thinking about buying stock in Apache, CNH Industrial, Home Depot, Ibio, or Vivus?
NEW YORK, Aug. 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APA, CNHI, HD, IBIO, and VVUS.
Aug 19, 2019 04:35 pm ET
iBio Inks 3D Bioprinting Agreement
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen...
Jun 19, 2019 08:00 am ET
iBio Announces First Agreement for Fill-Finish Services
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the activation of its new cGMP sterile fill-finish services operation via the signing of a supply agreement with a clinical-stage biopharmaceutical company developing...
Jun 03, 2019 08:00 am ET
iBio Launches New Sterile Fill-Finish Services
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. Designed for clients with...
Apr 01, 2019 08:30 am ET
iBio Announces Appointment of Thomas F. Isett to Board of Directors
iBio, Inc. (NYSE AMERICAN:IBIO), a biologics contract manufacturer and product developer with proprietary, “green” technologies for biopharmaceutical production, today announced the appointment of Thomas F. Isett to its Board of Directors,...
Dec 14, 2018 08:00 am ET
iBio Provides Status Update on its Continuing Litigation Against Fraunhofer
iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, announced today that the Second Complaint it filed in iBio’s litigation against the Fraunhofer organization – this time against Fraunhofer Gesellschaft (“FhG”),...
Dec 03, 2018 08:00 am ET
iBio to Present at Brazilian Ministry of Health’s Plant-Made Pharmaceutical Meeting
iBio, Inc. (NYSE AMERICAN:IBIO), a developer and manufacturer of biotherapeutics, today announced that it will present at the Plant-Based Technology Trends Meeting being held in Meireles, Fortaleza, Brazil from December 2-4, 2018. The meeting is...
Oct 02, 2018 08:00 am ET
iBio and CC-Pharming Hold First Design and Strategy Meeting
iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan...
Aug 22, 2018 04:10 pm ET
iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance
IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that NYSE Regulation has accepted the Company’s plan to regain compliance with the Exchange’s continued listing standards set forth in Section 1003(a)(iii) of the NYSE...
Jul 09, 2018 08:00 am ET
iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd. of Beijing, China
iBio, Inc. (NYSE AMERICAN:IBIO) today announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities for the Chinese biopharmaceutical market,...
Jun 26, 2018 06:59 pm ET
iBio, Inc. Closes $16,000,000 Public Offering
IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”), today announced that it has closed its previously announced underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting underwriting...
Jun 22, 2018 07:26 am ET
iBio, Inc. Prices $16,000,000 Public Offering
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” OR THE “COMPANY”), today announced the pricing of an underwritten public offering with expected total gross proceeds of approximately $16,000,000, before deducting underwriting discounts, commissions and...
Jun 08, 2018 04:30 pm ET
iBio, Inc. Announces Completion of 1-For-10 Reverse Stock Split
IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that its previously announced 1-for-10 reverse stock split of common stock became effective today at 4:10 p.m. (Eastern Time) (the “Effective Time”).  The Company’s common...
Jun 08, 2018 04:01 pm ET
iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that on June 6, 2018, the Company received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing...
Jun 05, 2018 08:30 am ET
iBio and ONEWAY Diagnostica Develop New Products for Brazil
iBio, Inc. (NYSE AMERICAN:IBIO) today announced a joint product development, manufacturing and revenue sharing agreement with ONEWAY Diagnostica of Brazil for novel point of care diagnostic products initially focused on Zika and Chikungunya virus...
May 31, 2018 08:30 am ET
iBio, Inc. Announces Reverse Stock Split
IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today a reverse split of its Common Stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1 for 10, effective on June 8, 2018 (the “Effective Date”).  The Company’s...
Mar 14, 2018 08:30 am ET
iBio Selects Lead Candidate for its Fibrosis Therapeutics Program
NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio”) announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a drug against fibrotic diseases, including systemic...
Mar 12, 2018 08:30 am ET
iBio Patent Issues in China on Protein Glycosylation Modification
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“iBio”) announced the expansion of its intellectual property portfolio with the issuance of a patent in China describing control of protein glycosylation.  The new patent, serial...
Mar 07, 2018 08:45 am ET
iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“iBio”) announced the expansion of its CDMO capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical applications.
Jan 05, 2018 05:00 pm ET
iBio, Inc. Provides Corporate Update
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today its receipt of notice that Staff of NYSE American LLC determined that the Company’s securities “. . . have been...
Nov 30, 2017 04:15 pm ET
iBio, Inc. Closes $4,500,000 Offering of Common Stock
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”), today announced the closing of its previously announced public offering of 22,500,000 shares of its common stock at a price to the...
Nov 29, 2017 09:00 am ET
iBio, Inc. Prices $4,500,000 Firm Commitment Offering of Common Stock
NEW YORK, Nov. 29, 2017 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”), today announced the pricing of a firm commitment public offering of 22,500,000 shares of its common stock at a price to the...
Nov 28, 2017 05:07 pm ET
iBio, Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, Nov. 28, 2017 (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN:IBIO) (“IBIO” OR THE “COMPANY”) announced today that it intends to launch an offering of shares of its common stock for sale in an underwritten public offering....
Nov 06, 2017 05:00 pm ET
iBio, Inc. Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court
NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today that it initiated litigation against Fraunhofer-Gesellschaft (Fraunhofer) by filing a complaint in the Court of Chancery of the State of Delaware to remedy the consequences of Fraunhofer’s fraud and theft of iBio’s technology and intellectual property.  This complaint follows iBio’s pending litigation filed in March 2015 against Fraunhofer USA, Inc., the U.S. unit of Fraunhofer....
Nov 06, 2017 05:00 pm ET
iBio, Inc. Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court
NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today that it initiated litigation against Fraunhofer-Gesellschaft (Fraunhofer) by filing a complaint in...
Oct 16, 2017 08:15 am ET
Aethlon Medical Announces Large-Scale Production Collaboration
SAN DIEGO, Oct. 16, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that it has established a collaboration with iBio, Inc. (NYSE AMERICAN: IBIO) to support potential large-scale production of the Aethlon Hemopurifier®.  iBio is a leading developer of plant-based biopharmaceuticals.
Sep 20, 2017 08:00 am ET
iBio, Inc. Intellectual Property Update
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, provided an update on recent patents and inventions....
Sep 19, 2017 05:55 pm ET
iBio Makes NYSE MKT Section 610(b) Public Announcement
NEW YORK, Sept. 19, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) – iBio, a leader in developing plant-based biopharmaceuticals, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended June 30, 2017 filed on September 15, 2017 with the Securities and Exchange Commission, the audited financial statements for the year ended June 30, 2017 included in the 10-K contained an audit opinion from its independent registered public accounting firm, which included a going concern emphasis of matter paragraph.    ...
Sep 18, 2017 08:00 am ET
iBio and TheoremDx Collaborate to Develop Proteins for Rapid Diagnostics Testing Products
NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) – iBio, with its subsidiary, iBio CDMO LLC in Bryan/College Station, Texas ("iBio CDMO"), has partnered with TheoremDx, Inc., in Edina, Minnesota, to develop proteins for rapid diagnostic testing products....
Jul 24, 2017 08:30 am ET
iBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital
NEW YORK, July 24, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE MKT:IBIO) (“iBio”), a leader in developing plant-based biopharmaceuticals, announced today that it has entered into a $16 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.  Upon execution of the agreement, LPC initially purchased $1.0 million worth of common stock at $0.40 per share.  After the SEC declares a registration statement effective relating to the transaction, iBio will have the right and the sole discretion to sell to LPC up to an additional $15.0...
May 04, 2017 04:01 pm ET
iBio, Inc. Provides Corporate Update at Annual Shareholders Meeting
iBio, Inc. (NYSE MKT: IBIO), a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual Shareholders Meeting held in Bryan, TX.
Jan 27, 2017 08:30 am ET
Court Schedules Hearing To Consider Approval Of Settlement Of Derivative Action
iBio, Inc. (NYSE MKT: IBIO) On January 20, 2017, the Supreme Court for the State of New York, County of New York, scheduled a hearing to consider approval of a settlement of the derivative action captioned Spencer Savage and Yousef Barakat, Derivatively on Behalf of iBio, Inc., Plaintiffs, v. Robert B. Kay, Arthur Y. Elliott, James T. Hill, Glenn Chang, Philip K. Russell, John D. McKey, and Seymour Flug, Defendants, and iBio, Inc., Nominal Defendant, Index No. 162407 / 2015 (N.Y. Sup. Ct.). That action has been settled according to the terms of a Stipulation of Settlement dated as of
Nov 21, 2016 08:31 am ET
Another iBio Plague Vaccine Patent Issues
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue of a new Canadian patent in the company's iBioModulator™ thermostable immunomodulator protein portfolio. The new patent, serial number 2692933, is entitled "Yersinia Pestis Antigens, Vaccine Compositions and Related Methods" and issued October 18, 2016. The patent includes claims covering plague antigens fused to the Company's iBioModulator™ thermostable immunomodulator, as well as vaccine compositions and a method for producing the
Nov 10, 2016 08:31 am ET
iBio Expands Product Development Capacity of cGMP Plant
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced completion of expanded product development capacity of its subsidiary, iBio CMO LLC, for the production of pharmaceutical proteins in hydroponically-grown green plants. This expansion enables iBio CMO's use of iBio proprietary technologies to conduct concurrent product development work for multiple clients in multiple product classes with time-saving transitions from laboratory-level feasibility and testing through cGMP production of active
Sep 29, 2016 08:30 am ET
iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies (Pty) Ltd
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products announced the successful application of its proprietary technologies to achieve the first milestone in its commercial development agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) of South Africa for the development and manufacture of an improved surfactant protein for the treatment of neonatal respiratory distress syndrome (RDS).
Aug 15, 2016 08:30 am ET
Implications of Court Decision in Favor of iBio Against Fraunhofer
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, commented further today on the impact of the recent Court decision in favor of iBio in its action against Fraunhofer and particularly to prevent Fraunhofer's August 8th press release from misleading the public about the implications of the decision.
Aug 04, 2016 08:31 am ET
iBio, Inc.'s Claims Against Fraunhofer Affirmed by Delaware Chancery Court
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced today that the Delaware Court of Chancery, where litigation brought by iBio against Fraunhofer USA Inc. has been pending, issued a decisive determination on July 29, 2016, in favor of iBio and against Fraunhofer. The Court affirmed iBio's exclusive ownership of all proprietary rights of any kind to technology in the area of plant-based technologies, techniques and methodologies, developed or acquired by Fraunhofer prior to or during the principal
Jul 05, 2016 08:31 am ET
iBio, Inc. Receives FDA Orphan Drug Designation for Fibrosis Product Candidate
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to iBio's investigational biotherapeutic product, iBio-CFB03, for the treatment of systemic sclerosis.
Jun 29, 2016 08:31 am ET
iBio, Inc. Receives New Patent for Its Biotherapeutic Products for Treatment of Fibrosis
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced the issue by the U.S. Patent and Trademark Office on June 14, 201 of a new patent covering the company's fibrosis therapeutics product pipeline.
Jun 07, 2016 08:31 am ET
Texas A&M University System and iBio Execute Joint Development Agreement for Plant-Produced Pharmaceuticals
iBio, Inc. (NYSE MKT: IBIO) - The Texas A & M University System (including Texas A & M University AgriLife Research, and the Texas A & M Institute of Infectious Animal Diseases (IIAD)) ("TAMUS"), has executed a joint development agreement with iBio, Inc., and its subsidiary, iBio CMO LLC in Bryan/College Station, Texas ("iBio") for the establishment of a collaborative program in plant-produced pharmaceuticals.
Apr 07, 2016 05:46 pm ET
iBio, Inc. Holds Annual Meeting in College Station, Texas
iBio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the iBio, Inc. (NYSE MKT: IBIO) Annual Meeting today, Chairman and Chief Executive Officer Robert B. Kay highlighted the Company's most important achievements since its last Annual Meeting -- first, the creation of a new subsidiary for product development and large-scale manufacturing using the Company's proprietary plant-based technologies, and second, significantly advancing the Company's own product candidates against fibrotic diseases toward human clinical trials targeted to commence in 2016.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.